Leaderboards/CNS Lymphoma Diagnosis and Treatment

CNS Lymphoma Diagnosis and Treatment

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Jurik Mutter
Stanford Medicine
2
Rong Wei
Peking University
3
Sarah Challenor
Royal Cornwall Hospital
4
Meifang Zhao
Jinhua Academy of Agricultural Sciences
5
Victor M. Orellana‐Noia
University of Virginia
6
Denise Carbonell
Singapore National Eye Center
7
Jakoba J. Eertink
Amsterdam Neuroscience
8
Montreh Tavakkoli
University of Pennsylvania
9
Andrés J. M. Ferreri
Vita-Salute San Raffaele University
10
Benjamin J. Stewart
University of Cambridge

Papers

1
Publication in HemaSphere (2024) [26 citations, W4399319862]
HemaSphere|2024
26 cit.
2
The development process of ‘fit-for-purpose’ imaging biomarkers to characterize the tumor microenvironment
Frontiers in Medicine|2024
5 cit.
3
Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET response
Haematologica|2025
1 cit.
4
Publication in Cancer Research (2025) [W4409691368]
Cancer Research|2025
0 cit.
5
Publication in Blood (2025) [W4417009636]
Blood|2025
0 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Olga Kolman
Siberian Federal University
2
Cyrus M. Ghajar
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
3
Ndiya Ogba
National Comprehensive Cancer Network
4
Ryan D. Cassaday
University of Washington
5
Leland Hu
First Affiliated Hospital of Xi'an Jiaotong University
6
Manon M. H. Huibers
Utrecht University
7
David Tucker
Royal Cornwall Hospital Trust
8
Stephen Yu
Simon Fraser University
9
Marcel Nijland
University Medical Center Groningen
10
Clémentine Sarkozy
Spinal Cord Injury BC

Papers

1
Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies
Cancer Cell|2024
75 cit.
2
Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study
Blood|2022
70 cit.
3
Unchecked oxidative stress in skeletal muscle prevents outgrowth of disseminated tumour cells
Nature Cell Biology|2022
57 cit.
4
Integrated molecular and multiparametric MRI mapping of high-grade glioma identifies regional biologic signatures
Nature Communications|2023
51 cit.
5
<scp>R‐miniCHOP</scp> versus <scp>R‐CHOP</scp> in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study
American Journal of Hematology|2023
31 cit.
6
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study
Journal of Clinical Oncology|2023
28 cit.
7
Integrated single cell analysis reveals co-evolution of malignant B cells and tumor micro-environment in transformed follicular lymphoma
Cancer Cell|2024
27 cit.
8
Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results
Blood|2023
20 cit.
9
Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis
European Journal of Cancer|2022
13 cit.
10
Low Mutational Burden of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren’s Syndrome
Cancers|2022
12 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Tim Lister
Las Cumbres Observatory Global Telescope Network
2
Lisa M. DeAngelis
Memorial Sloan Kettering Cancer Center
3
Franco Cavalli
Institute of Social and Preventive Medicine
4
Christian Gisselbrecht
Institut Universitaire de France
5
Henry S. Kaplan
Saint Louis University
6
Marco Ladetto
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
7
Elaine S. Jaffe
National Cancer Institute
8
Michael Weller
University Hospital of Zurich
9
Gerald Illerhaus
Klinikum Stuttgart
10
Hervé Tilly
Centre Virchow-Villermé

Papers

1
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
New England Journal of Medicine|2002
5.6k cit.
2
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Journal of Clinical Oncology|2014
5.6k cit.
3
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Blood|2017
1.7k cit.
4
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.
Journal of Clinical Oncology|1989
1.6k cit.
5
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Journal of Clinical Oncology|2010
1.6k cit.
6
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Blood|2010
1.6k cit.
7
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
JAMA Oncology|2020
1.5k cit.
8
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
The Lancet Oncology|2012
1.1k cit.
9
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
The Lancet|2010
1.1k cit.
10
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
The Lancet Oncology|2014
1k cit.

Reagents for CNS Lymphoma Diagnosis and Treatment

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 63

RIPA Buffer (10X)

#9806$93
View Evidence →
Cell Signaling TechnologyEvidence 65

Phospho-KAP-1 (Ser824) Antibody

#4127$153,362
View Evidence →
Cell Signaling TechnologyEvidence 65

STIM1 Antibody

#4916$317
View Evidence →

🌟 All-Time

Most validated

Agilent/Dako

Mutated melanoma-associated antigen 1

Cited in 8 papers
#M7259
View Evidence →
Innovative ResearchEvidence 72

Mouse Anti-Human CD1a Monoclonal Antibody, Alexa Fluor 488 Conjugated, Clone 143

#CD1A20
View Evidence →
Cell Signaling TechnologyEvidence 68

OX40L (D6K7R) Rabbit Monoclonal Antibody (BSA and Azide Free)

#51635$865
View Evidence →